ERNA:NASDAQ, Ernexa Therapeutics Inc.
ERNA stock overview
Ernexa Therapeutics Inc. (ERNA:NASDAQ) closed at $2.07 on October 23, 2026,
down 0.48% on the day.
The stock trades 97.1% below its 52-week high of $71.50
and 12.2% above its 52-week low of $1.84.
Ernexa Therapeutics Inc. is part of the Health Care sector.
Key figures
- Price
- $2.07
- Day change
- -0.48%
- Volume
- 5,674
- Average volume
- 52,790
- Market cap
- 3M+
- 52-week range
- $1.84 – $71.50
- 50-day average
- $3.58
- 200-day average
- $8.26
Price action over the past year
In 251 trading sessions since October 23, 2025, ERNA closed higher on 96 days (38%).
Its best day was May 12, 2026 (+66.57%) and its worst was February 6, 2026 (-44.12%).
The stock moved 10% or more in a single session 33 times.
It opened at least 5% above the previous day's high 6 times.
Recent signals
ERNA news
-
Oct 22, 2026:
Ernexa Therapeutics Highlights ERNA-101's Path Toward the Clinic and Differentiated Cell Therapy Platform in New "What This Means" Segment
-
Oct 22, 2026:
Ernexa Therapeutics Highlights ERNA-101's Path Toward the Clinic and Differentiated Cell Therapy Platform in New “What This Means” Segment
-
Oct 12, 2026:
Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series
-
Oct 6, 2026:
Ernexa Therapeutics' ERNA-101 Selected for Flash Talk Presentation at Nature Conferences' Next-Generation Cancer Therapeutics Meeting Co-Hosted by MD Anderson Cancer Center
-
Oct 1, 2026:
Ernexa Therapeutics CEO Corner Highlights Appointment of Dr. Robert J. Spiegel as Company Sharpens Oncology Focus and Advances ERNA-101 Toward the Clinic
-
Sep 30, 2026:
Ernexa Therapeutics Reports Compelling ERNA-101 Safety Results Across Three Critical IND-Enabling Studies, Advancing Toward Planned Q4 2026 IND
-
Sep 29, 2026:
Ernexa Therapeutics Selected for Emerging Track at 2026 Cell & Gene Meeting on the Mesa, Highlighting ERNA-101 and Focused Oncology Strategy
-
Sep 17, 2026:
Ernexa Therapeutics Appoints Accomplished Biopharmaceutical Executive Robert J. Spiegel, M.D., FACP, to Board of Directors
About Ernexa Therapeutics Inc.
Brooklyn ImmunoTherapeutics Inc is a clinical-stage biopharmaceutical company. It is developing IRX-2, a novel hd-IL-2 -based therapy, to treat patients with cancer. IRX-2 delivers hd-IL-2 and other key cytokines to potentially restore immune function in the tumor microenvironment, enabling the immune system to attack cancer cells.
Similar stocks
Find more stocks like ERNA with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.